- BPH Energy (BPH) investee Cortical Dynamics files submission with the FDA for its medical device, the Brain Anaesthesia Response Monitor (BARM)
- BARM measures the effects of anaesthetic drugs on brain electrical activity for surgical operations under general anaesthetic
- The technology is obtained from a model of how human electrical activity of the brain is generated
- On the market this morning, BPH Energy is up 3.39 per cent and is trading at 6.1 cents per share
BPH Energy (BPH) investee Cortical Dynamics has filed a submission with the US Food and Drug Administration (FDA) for its medical device, the Brain Anaesthesia Response Monitor (BARM).
BARM takes a physiological approach to measuring the effects of anaesthetic drugs on brain electrical activity for surgical operations under general anaesthetic.
The technology is obtained from a model of how human electrical activity of the brain is generated.
“BARM describes the electrical activity of populations of excitatory and inhibitory neurons within the cerebral cortex, and uses established physiological parameters such as the number of connections between neuronal populations, conduction velocities, and firing rates and thresholds,” the company said in an announcement.
“The model can produce the main features of spontaneous human EEG and the effects general anaesthetics have on the EEG providing anaesthetists with valuable feedback as to the depth of anaesthesia experienced by patients.”
Notably, Cortical was assisted in the FDA submission by MCRA, the leading US Regulatory Advisor for the Medical Device and Biologics industries.
On the market this morning, BPH Energy is up 3.39 per cent and is trading at 6.1 cents per share at 12:34 pm AEST.